利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

35 条记录 (耗时 0.027 秒)

    PROCESSES FOR THE PRODUCTION OF POLYMORPHIC FORMS OF RIFAXIMIN
    4.
    发明申请
    PROCESSES FOR THE PRODUCTION OF POLYMORPHIC FORMS OF RIFAXIMIN 审中-公开
    生产RIFAXIMIN多形态的方法

    公开(公告)号：US20120214989A1

    公开(公告)日：2012-08-23

    申请号：US13463714

    申请日：2012-05-03

    申请人： Giuseppe Claudio Viscomi ,  Manuela Campana ,  Dario Braga ,  Donatella Confortini ,  Vincenzo Cannata ,  Paolo Righi ,  Goffredo Rosini

    发明人： Giuseppe Claudio Viscomi ,  Manuela Campana ,  Dario Braga ,  Donatella Confortini ,  Vincenzo Cannata ,  Paolo Righi ,  Goffredo Rosini

    IPC分类号： C07D498/22

    CPC分类号： C07D498/22

    摘要： Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

    摘要翻译： 结晶多形态的利福昔明（INN）抗生素名为利福昔明α和利福昔明，并且结晶形式名为利福昔明γ，可用于生产含有利福昔明用于口服和局部使用的药物制剂，并通过结晶进行 将生的利福昔明热溶解在乙醇中，并通过在确定的温度下加入水并在一定的时间内引起产物的结晶，然后在受控条件下进行干燥，直到达到沉淀的含水量 最终产品是本发明的目的。

    Polymorphic forms α, β and γ of rifaximin
    5.
    发明授权
    Polymorphic forms α, β and γ of rifaximin 有权
    多形态α，＆bgr; 和利福昔明的γ

    公开(公告)号：US08158781B2

    公开(公告)日：2012-04-17

    申请号：US13041332

    申请日：2011-03-04

    申请人： Giuseppe Claudio Viscomi ,  Manuela Campana ,  Dario Braga ,  Donatella Confortini ,  Vincenzo Cannata ,  Paolo Righi ,  Goffredo Rosini

    发明人： Giuseppe Claudio Viscomi ,  Manuela Campana ,  Dario Braga ,  Donatella Confortini ,  Vincenzo Cannata ,  Paolo Righi ,  Goffredo Rosini

    IPC分类号： C07D498/22

    CPC分类号： C07D498/22 ,  C07B2200/13 ,  C07D491/22

    摘要： Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

    摘要翻译： 结晶多形态的利福昔明（INN）抗生素名为利福昔明α和利福昔明，并且结晶形式名为利福昔明γ，可用于生产含有利福昔明用于口服和局部使用的药物制剂，并通过结晶进行 将生的利福昔明热溶解在乙醇中，并通过在确定的温度下加入水并在一定的时间内引起产物的结晶，然后在受控条件下进行干燥，直到达到沉淀的含水量 最终产品是本发明的目的。

    PROCESSES FOR THE PRODUCTION OF POLYMORPHIC FORMS OF RIFAXIMIN
    8.
    发明申请
    PROCESSES FOR THE PRODUCTION OF POLYMORPHIC FORMS OF RIFAXIMIN 有权
    生产RIFAXIMIN多形态的方法

    公开(公告)号：US20110160449A1

    公开(公告)日：2011-06-30

    申请号：US13041346

    申请日：2011-03-04

    申请人： Giuseppe Claudio Viscomi ,  Manuela Campana ,  Dario Braga ,  Donatella Confortini ,  Vincenzo Cannata ,  Paolo Righi ,  Goffredo Rosini

    发明人： Giuseppe Claudio Viscomi ,  Manuela Campana ,  Dario Braga ,  Donatella Confortini ,  Vincenzo Cannata ,  Paolo Righi ,  Goffredo Rosini

    IPC分类号： C07D491/22

    CPC分类号： C07D498/22

    摘要： Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

    摘要翻译： 结晶多形态的利福昔明（INN）抗生素名为利福昔明α和利福昔明，并且结晶形式名为利福昔明γ，可用于生产含有利福昔明用于口服和局部使用的药物制剂，并通过结晶进行 将生的利福昔明热溶解在乙醇中，并通过在确定的温度下加入水并在一定的时间内引起产物的结晶，然后在受控条件下进行干燥，直到达到沉淀的含水量 最终产品是本发明的目的。

    POLYMORPHIC FORMS ALPHA, BETA AND GAMMA OF RIFAXIMIN
    9.
    发明申请
    POLYMORPHIC FORMS ALPHA, BETA AND GAMMA OF RIFAXIMIN 有权
    多聚体形式的阿尔法，BETA和游戏的RIFAXIMIN

    公开(公告)号：US20110160448A1

    公开(公告)日：2011-06-30

    申请号：US13041332

    申请日：2011-03-04

    申请人： Giuseppe Claudio Viscomi ,  Manuela Campana ,  Dario Braga ,  Donatella Confortini ,  Vincenzo Cannata ,  Paolo Righi ,  Goffredo Rosini

    发明人： Giuseppe Claudio Viscomi ,  Manuela Campana ,  Dario Braga ,  Donatella Confortini ,  Vincenzo Cannata ,  Paolo Righi ,  Goffredo Rosini

    IPC分类号： C07D498/22

    CPC分类号： C07D498/22 ,  C07B2200/13 ,  C07D491/22

    摘要： Crystalline polymorphous forms of rifaximin (INN) antibiotic named rifaximin α and rifaximin β, and a poorly crystalline form named rifaximin γ, useful in the production of medicinal preparations containing rifaximin for oral and topical use and obtained by means of a crystallization carried out by hot-dissolving the raw rifaximin in ethyl alcohol and by causing the crystallization of the product by addition of water at a determinate temperature and for a determinate period of time, followed by a drying carried out under controlled conditions until reaching a settled water content in the end product, are the object of the invention.

    摘要翻译： 结晶多形态的利福昔明（INN）抗生素名为利福昔明α和利福昔明，并且结晶形式名为利福昔明γ，可用于生产含有利福昔明用于口服和局部使用的药物制剂，并通过结晶进行 将生的利福昔明热溶解在乙醇中，并通过在确定的温度下加入水并在一定的时间内引起产物的结晶，然后在受控条件下进行干燥，直到达到沉淀的含水量 最终产品是本发明的目的。